Cargando…
Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
Even though cervical cancer is partly preventable, it still poses a great public health problem throughout the world. Current therapies have vastly improved the clinical outcomes of cervical cancer patients, but progress in new systemic treatment modalities has been slow in the last years. Especiall...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917788/ https://www.ncbi.nlm.nih.gov/pubmed/33670397 http://dx.doi.org/10.3390/ijms22041807 |
_version_ | 1783657777699225600 |
---|---|
author | Verhoeven, Yannick Quatannens, Delphine Trinh, Xuan Bich Wouters, An Smits, Evelien L.J. Lardon, Filip De Waele, Jorrit van Dam, Peter A. |
author_facet | Verhoeven, Yannick Quatannens, Delphine Trinh, Xuan Bich Wouters, An Smits, Evelien L.J. Lardon, Filip De Waele, Jorrit van Dam, Peter A. |
author_sort | Verhoeven, Yannick |
collection | PubMed |
description | Even though cervical cancer is partly preventable, it still poses a great public health problem throughout the world. Current therapies have vastly improved the clinical outcomes of cervical cancer patients, but progress in new systemic treatment modalities has been slow in the last years. Especially for patients with advanced disease this is discouraging, as their prognosis remains very poor. The pathogen-induced nature, the considerable mutational load, the involvement of genes regulating the immune response, and the high grade of immune infiltration, suggest that immunotherapy might be a promising strategy to treat cervical cancer. In this literature review, we focus on the use of PD-1 blocking therapy in cervical cancer, pembrolizumab in particular, as it is the only approved immunotherapy for this disease. We discuss why it has great clinical potential, how it opens doors for personalized treatment in cervical cancer, and which trials are aiming to expand its clinical use. |
format | Online Article Text |
id | pubmed-7917788 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79177882021-03-02 Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update Verhoeven, Yannick Quatannens, Delphine Trinh, Xuan Bich Wouters, An Smits, Evelien L.J. Lardon, Filip De Waele, Jorrit van Dam, Peter A. Int J Mol Sci Review Even though cervical cancer is partly preventable, it still poses a great public health problem throughout the world. Current therapies have vastly improved the clinical outcomes of cervical cancer patients, but progress in new systemic treatment modalities has been slow in the last years. Especially for patients with advanced disease this is discouraging, as their prognosis remains very poor. The pathogen-induced nature, the considerable mutational load, the involvement of genes regulating the immune response, and the high grade of immune infiltration, suggest that immunotherapy might be a promising strategy to treat cervical cancer. In this literature review, we focus on the use of PD-1 blocking therapy in cervical cancer, pembrolizumab in particular, as it is the only approved immunotherapy for this disease. We discuss why it has great clinical potential, how it opens doors for personalized treatment in cervical cancer, and which trials are aiming to expand its clinical use. MDPI 2021-02-11 /pmc/articles/PMC7917788/ /pubmed/33670397 http://dx.doi.org/10.3390/ijms22041807 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Verhoeven, Yannick Quatannens, Delphine Trinh, Xuan Bich Wouters, An Smits, Evelien L.J. Lardon, Filip De Waele, Jorrit van Dam, Peter A. Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update |
title | Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update |
title_full | Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update |
title_fullStr | Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update |
title_full_unstemmed | Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update |
title_short | Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update |
title_sort | targeting the pd-1 axis with pembrolizumab for recurrent or metastatic cancer of the uterine cervix: a brief update |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917788/ https://www.ncbi.nlm.nih.gov/pubmed/33670397 http://dx.doi.org/10.3390/ijms22041807 |
work_keys_str_mv | AT verhoevenyannick targetingthepd1axiswithpembrolizumabforrecurrentormetastaticcanceroftheuterinecervixabriefupdate AT quatannensdelphine targetingthepd1axiswithpembrolizumabforrecurrentormetastaticcanceroftheuterinecervixabriefupdate AT trinhxuanbich targetingthepd1axiswithpembrolizumabforrecurrentormetastaticcanceroftheuterinecervixabriefupdate AT woutersan targetingthepd1axiswithpembrolizumabforrecurrentormetastaticcanceroftheuterinecervixabriefupdate AT smitsevelienlj targetingthepd1axiswithpembrolizumabforrecurrentormetastaticcanceroftheuterinecervixabriefupdate AT lardonfilip targetingthepd1axiswithpembrolizumabforrecurrentormetastaticcanceroftheuterinecervixabriefupdate AT dewaelejorrit targetingthepd1axiswithpembrolizumabforrecurrentormetastaticcanceroftheuterinecervixabriefupdate AT vandampetera targetingthepd1axiswithpembrolizumabforrecurrentormetastaticcanceroftheuterinecervixabriefupdate |